Which has preferable valuation & earnings, ANL or PMN?

Adlai Nortye has higher revenue and earnings than Promis Neurosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 189.98 -$35.53M N/A N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is ANL or PMN more profitable?

Adlai Nortye's return on equity of 0.00% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Promis Neurosciences N/A -143.09% -109.15%

Does the media prefer ANL or PMN?

In the previous week, Promis Neurosciences had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 3 mentions for Promis Neurosciences and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.14 beat Promis Neurosciences' score of 0.34 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Promis Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, KYTX or PMN?

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$2.94 N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is KYTX or PMN more profitable?

Kyverna Therapeutics' return on equity of -81.92% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.92% -63.74% Promis Neurosciences N/A -143.09% -109.15%

Does the media prefer KYTX or PMN?

In the previous week, Promis Neurosciences had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Promis Neurosciences and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.90 beat Promis Neurosciences' score of 0.34 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Promis Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, PMN or CABA?

Cabaletta Bio is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is PMN or CABA more profitable?

Cabaletta Bio's return on equity of -128.27% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -143.09% -109.15% Cabaletta Bio N/A -128.27% -95.47%

Does the media refer more to PMN or CABA?

In the previous week, Cabaletta Bio had 3 more articles in the media than Promis Neurosciences. MarketBeat recorded 6 mentions for Cabaletta Bio and 3 mentions for Promis Neurosciences. Cabaletta Bio's average media sentiment score of 0.57 beat Promis Neurosciences' score of 0.34 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ELYM or PMN?

Promis Neurosciences has a consensus price target of $34.00, indicating a potential upside of 163.57%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Promis Neurosciences 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.88

Which has higher valuation & earnings, ELYM or PMN?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is ELYM or PMN more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Promis Neurosciences N/A -143.09% -109.15%

Is PMN or PRLD more profitable?

Prelude Therapeutics' return on equity of -75.35% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -143.09% -109.15% Prelude Therapeutics N/A -75.35% -44.39%

Does the media favor PMN or PRLD?

In the previous week, Promis Neurosciences had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Promis Neurosciences and 2 mentions for Prelude Therapeutics. Promis Neurosciences' average media sentiment score of 0.34 beat Prelude Therapeutics' score of -0.17 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Promis Neurosciences (PMN) Competitors

$12.90 -1.08 (-7.73%)

As of 09/3/2026 04:00 PM Eastern

Compare

PMN vs. ANL, KYTX, CABA, ELYM, and PRLD

Should you buy Promis Neurosciences stock or one of its competitors? Promis Neurosciences's main competitors and comparable companies include Adlai Nortye (ANL), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), Eliem Therapeutics (ELYM), and Prelude Therapeutics (PRLD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Promis Neurosciences compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Adlai Nortye has higher revenue and earnings than Promis Neurosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	189.98	-$35.53M	N/A	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

In the previous week, Promis Neurosciences had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 3 mentions for Promis Neurosciences and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.14 beat Promis Neurosciences' score of 0.34 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Promis Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adlai Nortye's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Promis Neurosciences	N/A	-143.09%	-109.15%

Adlai Nortye currently has a consensus price target of $24.25, suggesting a potential upside of 64.41%. Promis Neurosciences has a consensus price target of $34.00, suggesting a potential upside of 163.57%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Adlai Nortye has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Summary

Adlai Nortye beats Promis Neurosciences on 7 of the 13 factors compared between the two stocks.

How does Promis Neurosciences compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Kyverna Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Kyverna Therapeutics' return on equity of -81.92% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Promis Neurosciences	N/A	-143.09%	-109.15%

Kyverna Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 259.28%. Promis Neurosciences has a consensus target price of $34.00, suggesting a potential upside of 163.57%. Given Kyverna Therapeutics' higher possible upside, research analysts plainly believe Kyverna Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

In the previous week, Promis Neurosciences had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Promis Neurosciences and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.90 beat Promis Neurosciences' score of 0.34 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Promis Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kyverna Therapeutics beats Promis Neurosciences on 7 of the 13 factors compared between the two stocks.

How does Promis Neurosciences compare to Cabaletta Bio?

Promis Neurosciences (NASDAQ:PMN) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, Cabaletta Bio had 3 more articles in the media than Promis Neurosciences. MarketBeat recorded 6 mentions for Cabaletta Bio and 3 mentions for Promis Neurosciences. Cabaletta Bio's average media sentiment score of 0.57 beat Promis Neurosciences' score of 0.34 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.1% of Promis Neurosciences shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cabaletta Bio is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Cabaletta Bio's return on equity of -128.27% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-143.09%	-109.15%
Cabaletta Bio	N/A	-128.27%	-95.47%

Promis Neurosciences has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.27, indicating that its share price is 227% more volatile than the broader market.

Promis Neurosciences presently has a consensus target price of $34.00, suggesting a potential upside of 163.57%. Cabaletta Bio has a consensus target price of $15.33, suggesting a potential upside of 340.61%. Given Cabaletta Bio's higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Cabaletta Bio beats Promis Neurosciences on 9 of the 14 factors compared between the two stocks.

How does Promis Neurosciences compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Eliem Therapeutics' return on equity of -47.03% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Promis Neurosciences	N/A	-143.09%	-109.15%

Promis Neurosciences has a consensus price target of $34.00, indicating a potential upside of 163.57%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

In the previous week, Promis Neurosciences had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Promis Neurosciences and 0 mentions for Eliem Therapeutics. Promis Neurosciences' average media sentiment score of 0.34 beat Eliem Therapeutics' score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Promis Neurosciences	Neutral

Summary

Promis Neurosciences beats Eliem Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Promis Neurosciences compare to Prelude Therapeutics?

Promis Neurosciences (NASDAQ:PMN) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Promis Neurosciences currently has a consensus target price of $34.00, suggesting a potential upside of 163.57%. Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 46.03%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Promis Neurosciences is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Prelude Therapeutics' return on equity of -75.35% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-143.09%	-109.15%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Promis Neurosciences has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Promis Neurosciences has higher earnings, but lower revenue than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A
Prelude Therapeutics	$12.14M	34.51	-$99.50M	-$0.73	N/A

In the previous week, Promis Neurosciences had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Promis Neurosciences and 2 mentions for Prelude Therapeutics. Promis Neurosciences' average media sentiment score of 0.34 beat Prelude Therapeutics' score of -0.17 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Promis Neurosciences beats Prelude Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Promis Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMN vs. The Competition

Export

Metric	Promis Neurosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$125.32M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.51	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	2.34	16.29	12.89	6.14
Net Income	-$39.72M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-6.39%	0.34%	0.60%	-0.27%
1 Month Performance	-4.94%	8.52%	5.73%	0.68%
1 Year Performance	20.00%	52.66%	25.35%	14.84%

Promis Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMN Promis Neurosciences	2.8883 of 5 stars	$12.90 -7.7%	$34.00 +163.6%	+12.2%	$125.32M	N/A	N/A	5
ANL Adlai Nortye	1.829 of 5 stars	$15.06 +9.6%	$24.25 +61.0%	+728.7%	$549.60M	$5M	N/A	127	Positive News
KYTX Kyverna Therapeutics	1.7179 of 5 stars	$8.61 -2.6%	$30.00 +248.4%	+124.5%	$546.70M	N/A	N/A	96
CABA Cabaletta Bio	2.3431 of 5 stars	$3.25 +0.9%	$15.33 +371.8%	+121.7%	$545.94M	N/A	N/A	50	Analyst Forecast
ELYM Eliem Therapeutics	N/A	$17.84 +8.8%	N/A	+574.9%	$530.78M	N/A	N/A	9	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMN) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Promis Neurosciences (PMN) Competitors

PMN vs. ANL, KYTX, CABA, ELYM, and PRLD

How does Promis Neurosciences compare to Adlai Nortye?

Summary

How does Promis Neurosciences compare to Kyverna Therapeutics?

Summary

How does Promis Neurosciences compare to Cabaletta Bio?

Summary

How does Promis Neurosciences compare to Eliem Therapeutics?

Summary

How does Promis Neurosciences compare to Prelude Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Promis Neurosciences (PMN) Competitors

PMN vs. ANL, KYTX, CABA, ELYM, and PRLD

How does Promis Neurosciences compare to Adlai Nortye?

Which has preferable valuation & earnings, ANL or PMN?

Does the media prefer ANL or PMN?

Is ANL or PMN more profitable?

Do analysts prefer ANL or PMN?

Do institutionals and insiders hold more shares of ANL or PMN?

Which has more volatility and risk, ANL or PMN?

Summary

How does Promis Neurosciences compare to Kyverna Therapeutics?

Which has more risk & volatility, KYTX or PMN?

Do insiders & institutionals have more ownership in KYTX or PMN?

Is KYTX or PMN more profitable?

Do analysts recommend KYTX or PMN?

Which has stronger valuation & earnings, KYTX or PMN?

Does the media prefer KYTX or PMN?

Summary

How does Promis Neurosciences compare to Cabaletta Bio?

Does the media refer more to PMN or CABA?

Do insiders and institutionals hold more shares of PMN or CABA?

Which has better earnings & valuation, PMN or CABA?

Is PMN or CABA more profitable?

Which has more risk & volatility, PMN or CABA?

Do analysts rate PMN or CABA?

Summary

How does Promis Neurosciences compare to Eliem Therapeutics?

Which has higher valuation & earnings, ELYM or PMN?

Do institutionals & insiders hold more shares of ELYM or PMN?

Is ELYM or PMN more profitable?

Do analysts prefer ELYM or PMN?

Which has more risk and volatility, ELYM or PMN?

Does the media prefer ELYM or PMN?

Summary

How does Promis Neurosciences compare to Prelude Therapeutics?

Do analysts recommend PMN or PRLD?

Is PMN or PRLD more profitable?

Which has more volatility & risk, PMN or PRLD?

Do institutionals and insiders have more ownership in PMN or PRLD?

Which has stronger valuation and earnings, PMN or PRLD?

Does the media favor PMN or PRLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools